ストックスクリーナーアプリを入手
428.84
0.08%
-0.3431
前日終値:
$429.18
開ける：
$427.07
24時間の取引高:
477.24K
Relative Volume:
1.35
時価総額：
$9.50B
収益：
-
当期純損益:
$-518.67M
株価収益率:
-17.07
EPS:
-25.12
ネットキャッシュフロー:
$-438.32M
1週間 パフォーマンス:
+3.10%
1か月 パフォーマンス:
-3.22%
6か月 パフォーマンス:
+25.83%
1年 パフォーマンス:
+96.90%
1日の値動き範囲:
$393.61
$434.48
1週間の範囲:
$393.61
$436.84
52週間の値動き範囲:
$213.71
$463.62
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
名前
Madrigal Pharmaceuticals Inc
セクター
電話
404-380-9263
住所
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
MDGL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
427.86 | 9.57B | 0 | -518.67M | -438.32M | -25.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
420.39 | 108.30B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
653.93 | 69.37B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
479.74 | 62.38B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
830.42 | 51.50B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
165.09 | 34.94B | 398.11M | -1.03B | -868.57M | -5.7032 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-15 | 開始されました | Truist | Buy |
| 2025-09-04 | 再開されました | H.C. Wainwright | Buy |
| 2025-02-28 | アップグレード | B. Riley Securities | Neutral → Buy |
| 2025-02-27 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-06-28 | 開始されました | Cantor Fitzgerald | Neutral |
| 2024-06-11 | 開始されました | Wolfe Research | Outperform |
| 2024-04-22 | 開始されました | BofA Securities | Underperform |
| 2024-03-15 | アップグレード | B. Riley Securities | Sell → Neutral |
| 2024-03-06 | 開始されました | Citigroup | Buy |
| 2024-02-26 | ダウングレード | B. Riley Securities | Neutral → Sell |
| 2022-12-20 | 繰り返されました | Oppenheimer | Outperform |
| 2022-12-19 | 繰り返されました | H.C. Wainwright | Buy |
| 2022-12-19 | 繰り返されました | Piper Sandler | Overweight |
| 2022-12-19 | アップグレード | Raymond James | Underperform → Mkt Perform |
| 2022-07-08 | ダウングレード | B. Riley Securities | Buy → Neutral |
| 2021-10-07 | 開始されました | Jefferies | Buy |
| 2021-08-06 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-05-20 | 再開されました | Goldman | Buy |
| 2020-11-24 | 再開されました | Evercore ISI | Outperform |
| 2020-11-06 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-07-31 | 開始されました | Piper Sandler | Overweight |
| 2020-06-05 | 開始されました | BMO Capital Markets | Market Perform |
| 2020-05-05 | 開始されました | Chardan Capital Markets | Buy |
| 2020-01-30 | 開始されました | Canaccord Genuity | Buy |
| 2020-01-09 | アップグレード | UBS | Neutral → Buy |
| 2019-11-07 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-06-25 | 開始されました | Stifel | Hold |
| 2019-06-10 | アップグレード | B. Riley FBR | Neutral → Buy |
| 2019-02-28 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-02-22 | 開始されました | SVB Leerink | Outperform |
| 2019-01-23 | 開始されました | UBS | Neutral |
| 2018-12-14 | 開始されました | Wolfe Research | Outperform |
| 2018-12-12 | 開始されました | B. Riley FBR | Neutral |
| 2018-11-19 | ダウングレード | Raymond James | Mkt Perform → Underperform |
| 2018-11-16 | アップグレード | Evercore ISI | In-line → Outperform |
| 2018-09-04 | 開始されました | Citigroup | Buy |
| 2018-08-06 | ダウングレード | Goldman | Buy → Neutral |
| 2018-06-28 | 開始されました | Raymond James | Mkt Perform |
すべてを表示
Madrigal Pharmaceuticals Inc (MDGL) 最新ニュース
How Madrigal Pharmaceuticals Inc. stock reacts to global recession fearsMarket Activity Summary & Weekly High Return Stock Forecasts - newser.com
How to escape a deep drawdown in Madrigal Pharmaceuticals Inc.Weekly Gains Report & Community Verified Trade Alerts - newser.com
Is Madrigal Pharmaceuticals Inc. trending in predictive chart modelsEarnings Trend Report & Technical Buy Zone Confirmation - newser.com
Can Madrigal Pharmaceuticals Inc. stock hit record highs againPortfolio Performance Summary & Technical Confirmation Trade Alerts - newser.com
Madrigal Pharmaceuticals Experiences Evaluation Revision Amid Strong Market Performance - Markets Mojo
Madrigal (MDGL) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
Madrigal to Present New Data from the Company’s MASH Program at AASLD’s The Liver Meeting 2025 - The Manila Times
Madrigal Pharmaceuticals Inc. stock chart pattern explainedJuly 2025 Rallies & Real-Time Market Trend Scan - newser.com
Madrigal (NASDAQ: MDGL) to present cirrhosis and real-world Rezdiffra data at AASLD 2025 - Stock Titan
Will Madrigal Pharmaceuticals Inc. (YDO1) stock keep raising dividendsBond Market & Capital Efficiency Focused Ideas - newser.com
How strong is Madrigal Pharmaceuticals Inc. (YDO1) stock earnings growthMarket Performance Report & Expert Approved Momentum Trade Ideas - newser.com
Madrigal Pharmaceuticals Inc. stock trendline breakdownPortfolio Value Summary & Stepwise Trade Execution Plans - newser.com
Chart based exit strategy for Madrigal Pharmaceuticals Inc.Quarterly Investment Review & Precise Buy Zone Identification - newser.com
How forex fluctuations impact Madrigal Pharmaceuticals Inc. (YDO1) stockEarnings Trend Report & Daily Technical Stock Forecast Reports - newser.com
Statistical indicators supporting Madrigal Pharmaceuticals Inc.’s strengthTrade Signal Summary & Expert Approved Momentum Ideas - newser.com
How to integrate Madrigal Pharmaceuticals Inc. into portfolio analysis toolsMarket Risk Summary & Reliable Intraday Trade Alerts - newser.com
Will Madrigal Pharmaceuticals Inc. (YDO1) stock profit from AI boom2025 Earnings Impact & Daily Chart Pattern Signals - Fundação Cultural do Pará
Is it too late to sell Madrigal Pharmaceuticals Inc.Quarterly Risk Review & Low Drawdown Trading Strategies - newser.com
Madrigal Pharmaceuticals set to unveil Q3 2025 financial results on November 4 - Traders Union
Using RSI to spot recovery in Madrigal Pharmaceuticals Inc.July 2025 Review & Daily Technical Forecast Reports - newser.com
Is Madrigal Pharmaceuticals Inc a good long term investmentProtective Put Strategies & Unlock Free Weekly Portfolio Checkups - earlytimes.in
Madrigal Pharmaceuticals: Rezdiffra Commercialization Bode Well For Continued Growth MDGL - Seeking Alpha
Madrigal Pharmaceuticals Inc (MDGL) 財務データ
収益
当期純利益
現金流量
EPS
1.06%
1.45%
大文字化:
|
ボリューム (24 時間):